ARWR
Arrowhead Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow -3.1% ·
net new positions -10.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 133 | +6 | 82.36M | $6.29B | +14 | −7 |
| Q1 2026 | 129 | +9 | 82.68M | $4.92B | +14 | −6 |
| Q4 2025 | 119 | +2 | 83.16M | $5.52B | +3 | — |
| Q3 2025 | 18 | 0 | 61.93M | $2.14B | +1 | −2 |
| Q2 2025 | 16 | +2 | 54.75M | $865.08M | +2 | — |
| Q1 2025 | 11 | +1 | 14.99M | $191.04M | +1 | — |
| Q4 2024 | 10 | -1 | 13.46M | $253.12M | +1 | −2 |
| Q3 2024 | 10 | +1 | 7.88M | $152.69M | +1 | — |
| Q2 2024 | 9 | — | 6.44M | $167.29M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 6.02M | — | $113.11M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.95M | -0.3% | $55.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.95M | -0.3% | $55.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 2.05M | +0.5% | $38.62M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Millennium Management ✦ | 914.55K | +41.7% | $17.19M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 794.37K | +281.3% | $14.93M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 368.00K | -68.8% | $6.92M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 368.00K | -68.8% | $6.92M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Fisher Asset Management ✦ | 142.94K | +16.9% | $2.69M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Marshall Wace ✦ | 86.63K | New | $1.63M | 0.0% | New | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 75.86K | -0.8% | $1.43M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 55.40K | -10.5% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Wellington Management ✦ | 55.40K | -10.5% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Wellington Management ✦ | 55.40K | -10.5% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Wellington Management ✦ | 55.40K | -10.5% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.63M | 0.0% |
Exited
| Adage Capital Partners | $6.78M | was 0.0% |
| Renaissance Technologies | $4.48M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 7 holders, 11.03M shares, $23.90M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.00K sh · $173,920
Director · 11.60K sh · $1.01M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology